Initiation of HAART at higher CD4 cell counts is associated with a lower frequency of antiretroviral drug resistance mutations at virologic failure

Journal of Acquired Immune Deficiency Syndromes

Volumn 51, Issue 4, 2009, Pages 450-453

  Uy, Jonathan ^a,d   Armon, Carl ^b   Buchacz, Kate ^c   Wood, Kathy ^b   Brooks, John T ^c   Kb, J T B ^c   Tong, Tony ^c   Moorman, Anne ^c   Wood, Kathleen C ^b   Baker, Rose K ^b   Richardson, James T ^b   Hankerson, Darlene ^b   Palella, Frank J ^e   Chmiel, Joan S ^e   Chawla, Aditya ^e   Enyia, Onyinye ^e   Lichtenstein, Kenneth A ^f   Stewart, Cheryl ^f   Hammer, John ^g   Young, Benjamin ^g   Greenberg, Kenneth S ^g   Widick, Barbara ^g   Axinn, Joslyn D ^g   Yangco, Bienvenido G ^h   Halkias, Kalliope ^h   Ward, Douglas J ⁱ   Fiorentino, Charles A ⁱ   Fuhrer, Jack ^j   Ording Bauer, Linda ^j   Kelly, Rita ^j   Esteves, Jane ^j   Tedaldi, Ellen M ^k   Christian, Ramona A ^k   Ruley, Faye ^k   Nimmons, Atiya ^k   Novak, Richard M ^a   Wendrow, Andrea ^a   more..

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b CERNER CORPORATION   (United States)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^d BRISTOL MYERS SQUIBB   (United States)

^e NORTHWESTERN UNIVERSITY   (United States)

^f NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

^g ROSE MEDICAL CENTER   (United States)

^h INFECTIOUS DISEASE RESEARCH INSTITUTE   (United States)

ⁱ Dupont Circle Physicians Group   (United States)

^j STONY BROOK UNIVERSITY   (United States)

^k TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

Genotype; HIV; Viral drug resistance

Indexed keywords

ANTIRETROVIRUS AGENT; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; FEMALE; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MUTATION RATE; PRIORITY JOURNAL; TREATMENT FAILURE; VIRUS MUTATION; VIRUS RESISTANCE;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HUMANS; MALE; MUTATION;

EID: 68049120239     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3181acb630     Document Type: Article

References (10)

1. Panel on Antiretroviral Guidelines for Adult and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Department of Health and Human Services; January 29, 2008. Available at: http://aidsinfo.nih.gov. Accessed May 21, 2009.
2. Panel on Antiretroviral Guidelines for Adult and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Department of Health and Human Services; October 16, 2006. Available at: http://aidsinfo.nih.gov. Accessed May 21, 2009.
3. Kitahata MM, Gange SJ, Abraham AG, et al. Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med. 2009;360:1815-1826.
4. When To Start Consortium. Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet. 2009;373:1352-1363.
5. Palella FJ Jr, Baker RK, Moorman AC, et al. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr. 2006;43:27-34. (Pubitemid 44306484)
6. May M, Sterne JA, Sabin C, et al. Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies. AIDS. 2007;21:1185-1197. (Pubitemid 46763289)
7. 3 does not increase incidence or risk of peripheral neuropathy, anemia, or renal insufficiency. J Acquir Immune Defic Syndr. 2008;47:27-35.
8. Johnson VA, Brun-Vezinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1: Fall 2006. Top HIV Med. 2006;14:125-130.
9. Phillips A, Leen C, Wilson A, et al. Risk of extensive virological failure to the three original antiretroviral drug classes over long-term follow-up from the start of therapy in patients with HIV infection: an observational cohort study. Lancet. 2007;370:1923-1928. (Pubitemid 350193334)
10. Wheeler W, Mahle K, Bodnar U, et al. Antiretroviral drug-resistance mutations and subtypes in drug-naive persons newly diagnosed with HIV-1 infection, US, March 2003 to October 2006. Presented at: 14th Conference on Retroviruses and Opportunistic Infections; February 25-28, 2007; Los Angeles, CA. Abstract 648.